Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Materials

BioNexus Gene Lab Corp. (BGLC)

NCM · Specialty Chemicals

$1.35-0.02 (-1.46%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$3.3M
P/E (TTM)
EPS
$-1.47
Div Yield
52W Range
$1.07–$8.98
Beta
2.21

Company overview

BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Peers in Specialty Chemicals

All in industry →

Recent press releases

BioNexus Gene Lab Corp. has not issued a press release in this window.

SEC filings

All filings →

BioNexus Gene Lab Corp. has not filed an SEC document in this window.

BioNexus Gene Lab Corp. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
47,830 sh+226.5%

People at BioNexus Gene Lab Corp.

All people →

No officers or directors have been indexed for BioNexus Gene Lab Corp..

Quarterly financials

Full financials →
Revenue trend
03/25
$3.1K
NI
06/25
$1.8M
NI -$616.2K
09/25
$2.5M
NI -$709.0K
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.40
Prior: $-0.34
Revenue sparkline